This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This is just the third year that RSNA has offered a dedicated track on nuclearmedicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. 9:30 a.m. |
Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Food and Drug Administration, with a decision expected by the end of 2023. Donanemab is currently under review for approval by the U.S.
The Society introduced a new slate of officers, and recognized new Fellows, during its SNMMI 2023 Annual Meeting , held June 24-27 in Chicago, IL. The potential impact of nuclearmedicine in the care of patients dealing with cancer, heart disease, brain disease, and other challenges is enormous,” she said. “We
Theranostics pairs diagnostic biomarkers that can be visualized on nuclearmedicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.
New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC), according to a presentation at the recent Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting.
His research interests include using structural and functional MRI -- particularly ultrahigh-field, 7-tesla MRI -- to map brain microstructure and develop neurosurgical treatment of brain tumors, epilepsy, and neurodegenerative and movement disorders such as Parkinson's disease, essential tremor, and dystonia. Elliot Fishman, MD.
An emerging radioligand therapy could be particularly effective for controlling advanced sarcoma compared to other cancers, according to research presented June 8 in a Young Investigator Award session at the Society of NuclearMedicine and Molecular Imaging (SNMMI) meeting in Toronto. Image courtesy of SNMMI.
CHICAGO -- GE HealthCare (GEHC) brought new CT and MRI scanners and a range of AI software applications to McCormick Place for RSNA 2023. Interventional In image-guided surgery activities, GEHC showcased two new AI applications previously presented at ECR 2023. MRI GEHC unveiled Signa Champion, a 1.5-tesla,
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans, according to a study published April 11 in the Journal of NuclearMedicine. FAPI-PET either confirmed or ruled out the disease in all cases, the group found.
Thomas Hope, MD, a radiologist and nuclearmedicine physician at the University of California, San Francisco (UCSF), said that approval of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand has driven a marked interest and excitement about theranostics and radioligand therapies (RLT). Hope added.
Based on a novel clustering framework using sparse canonical correlation analysis (SCCA), the integrated approach was successful in identifying four subtypes of Alzheimer’s disease and the top genes associated with each, according to the authors of the study, “An SCCA-clustering framework for Alzheimer’s disease subtyping using tau PET and genomics.”
CHICAGO – Gallium-68 (Ga-68) RM2-PET/MRI is better than MRI alone for detecting relapse in prostate cancer patients, according to research presented November 26 at RSNA 2023. Therefore, Ga-68 RM2-PET should be considered in addition to PSMA-PET in BCR prostate cancer patients to aid in disease detection and management decision, she suggested.
christine.book Mon, 06/26/2023 - 12:46 June 26, 2023 — PET imaging with 68Ga-FAPI offers a feasible, reliable, and reproducible method for evaluating disease activity in rheumatoid arthritis, according to new research presented at the 2023 Society of NuclearMedicine and Molecular Imaging Annual Meeting.
christine.book Thu, 06/29/2023 - 12:17 June 29, 2023 — A study presented this week during the 2023 Society of NuclearMedicine and Molecular Imaging (SNMMI) Annual Meeting, SNMMI 2023 , found that personalized dosing of men with prostate cancer resulted in improved patient outcomes. Approved by the U.S.
Theranostics pairs diagnostic biomarkers that can be visualized on nuclearmedicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.
Our research shows that 18F-flurpiridaz stress cardiac PET imaging is excellent for diagnosing significant coronary artery disease even in obese patients, and at a lower radiation dose than traditional 99mTC-SPECT MPI,” stated Patel.
30, 2025 Earlier this month, the Society of NuclearMedicine and Molecular Imaging (SNMMI) and the Alzheimers Association released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Thu, 01/30/2025 - 10:20 Jan.30,
Mahmood was presented the award by the Society of NuclearMedicine and Molecular Imaging (SNMMI) at its 2023 Annual Meeting. Award recipients will have initiated, developed, and successfully implemented unique and significant transformative value within the field of nuclearmedicine and molecular imaging.
GE HealthCare introduced the MINItrace Magni at the Society of NuclearMedicine and Molecular Imaging annual meeting (SNMMI) annual meeting, a newly designed, small-footprint cyclotron for in-house production of commercial PET radiotracers. The system’s 21 cm digital detector offers a 1.6-times
milla1cf Wed, 10/11/2023 - 13:08 October 11, 2023 — A new imaging agent, 68Ga-ABY-025 , can predict early metabolic response to human epidermal growth factor receptor 2 ( HER2 )-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the September issue of The Journal of NuclearMedicine.
milla1cf Tue, 08/15/2023 - 16:28 August 15, 2023 — In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. For more information: www.snmmi.org Tuesday, August 15, 2023 - 16:28
mtaschetta-millane Sat, 06/24/2023 - 17:00 June 24, 2023 — A new ultra-high resolution (UHR) brain PET scanner may have the ability to characterize previously indistinguishable brain regions that are known to be involved in Alzheimer’s disease , depressive disorders, visual attention disorders, tinnitus, and other conditions.
mtaschetta-millane Sun, 06/25/2023 - 14:00 June 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated, according to research presented at the 2023 Society of NuclearMedicine and Molecular Imaging Annual Meeting.
milla1cf Wed, 06/28/2023 - 20:28 June 28, 2023 — GE HealthCare is set to unveil SIGNA PET/MR AIR [i] , at the Society of NuclearMedicine and Molecular Imaging ( SNMMI) 2023 annual meeting. The recent approval of drugs with disease modifying potential require additional imaging of patients with both MR and PET.
milla1cf Mon, 06/24/2024 - 20:34 June 24, 2024 — The Radiological Society of North America ( RSNA ) announced the 2023 impact factors today for its suite of journals. Radiology, RSNA’s leading medical imaging research journal, was cited nearly 60,000 times, according to the Clarivate Analytics Journal Citation Reports.
milla1cf Wed, 07/26/2023 - 20:36 July 26, 2023 — A molecular imaging tool developed by researchers at the University of California’s two nationally ranked medical centers, UCLA and UCSF , helps improve the accuracy of predicting the risk of cancer recurrence in patients with intermediate to high-risk prostate cancer who undergo surgery.
milla1cf Mon, 06/19/2023 - 19:27 June 19, 2023 — NorthStar Medical Technologies, LLC , a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., NorthStar’s commercialized, U.S.-based
milla1cf Fri, 06/23/2023 - 22:09 June 23, 2023 — A combination of pretherapy imaging and dosimetry can help ensure that patients with refractory differentiated thyroid cancer obtain the maximum benefit from radioactive iodine treatments following redifferentiation therapy.
milla1cf Wed, 05/31/2023 - 20:52 May 31, 2023 — GE HealthCare announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare’s growing Effortless Recon DL portfolio. link] Wednesday, May 31, 2023 - 20:52 Gallen in Switzerland [vii].
christine.book Mon, 12/04/2023 - 11:29 December 4, 2023 — Ajay Gupta, MD, MS , has been named chair of the Department of Radiology at Columbia University Vagelos College of Physicians and Surgeons and radiologist-in-chief at NewYork-Presbyterian/CUIMC. More information: www.cuimc.columbia.edu Monday, December 4, 2023 - 11:29
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 1.06 ± 0.05
Dr. Summers said LLM tools could be used to extract important information from other text-based radiology reports and medical records, and as a tool for identifying disease biomarkers. “My They have the potential to do things that we've had difficulty doing with traditional pre-large language models.”
christine.book Wed, 11/08/2023 - 11:38 November 8, 2023 — The American Society of Radiologic Technologists (ASRT) is encouraging the imaging community to recognize an important date for a vital discovery this week. For his work, Roentgen was awarded the first Nobel Prize in physics in 1901.
This inclusion in the NCCN Guidelines comes after the Society of NuclearMedicine and Molecular Imaging ( SNMMI ) recently published Appropriate Use Criteria to guide referring and imaging physicians in appropriate use of estrogen receptor (ER)-targeted PET imaging with 16α- 18 F-fluoro-17ß Fluoroestradiol. doi: 10.2967/jnumed.123.265420
These capabilities will help them develop and deliver products with the potential to improve care for even more patients with serious disease. “In Mr. Merrick concluded, “This is a very exciting and dynamic time for NorthStar and all those involved in nuclearmedicine.
As Theranostics and the use of radiopharmaceutical therapy (RPT) to treat cancer and other diseases have become more prevalent, interest in using dosimetry to personalize RPT treatments has grown. 2023 May 22;68(11). v MIM SurePlan MRT is also trusted globally, with installations in 23 countries spanning four continents. 121.262305. [ii]
Ultrasound model predicts liver disease progression. Horowitz, et al, Medical Hypotheses , October 13, 2023. Commercially Available Chest Radiograph AI Tools for Detecting Airspace Disease, Pneumothorax, and Pleural Effusion. Plesner, et al, Radiology , September 26, 2023. SPECT/CT reveals heart’s response to tafamidis.
more than 6 million Americans have Alzheimer's disease, a debilitating and far-reaching disease that accounts for 60% to 80% of dementia cases, and by 2050, this number is projected to rise to nearly 13 million, according to Alzheimer’s Disease International. The disease affects memory, thinking, and behavior. In the U.S.,
christine.book Mon, 06/26/2023 - 11:55 June 26, 2023 — A first-in-human evaluation of the novel theranostic pair 68Ga-DOTA-5G / 177Lu-DOTA-ABM-5G has confirmed its ability to successfully detect metastatic pancreatic cancer and visualize targeted treatment of the disease. Wagner, Jr., Image of the Year.
In an article posted on May 11, 2023, by the Global Coalition for Radiotherapy , he spoke about the commitment to deliver care despite the challenges. Attacking a children's hospital, where children are treated for cancer and other serious diseases, is not just a war crime; it is beyond the bounds of humanity.
christine.book Tue, 04/04/2023 - 10:16 April 4, 2023 — In support of an increased funding recommendation for the National Institutes of Health (NIH) in federal fiscal year (FY) 2024, William T. billion over FY 2023 levels, and in addition the release of the 21st Century Cures funds.
milla1cf Wed, 05/03/2023 - 22:37 May 3, 2023 — Artificial intelligence (AI) technology in the medical field has the possibility to automate diagnoses, decrease physician workload, and even to bring specialized healthcare to people in rural areas or developing countries. However, with possibility comes potential pitfalls. and Akiko K.
Food and Drug Administration (FDA), according to a study published January 3 in the Journal of NuclearMedicine. These data confirm the utility of PSMA-PET staging in high-risk disease and suggest that additional study is needed to refine patient selection in intermediate-risk disease, the group wrote.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content